Could Pfizer Stock Be Your Ticket to Generational Wealth?

Pfizer stock has declined over 50% from its 2021 peak, driving its dividend yield to 6.8%. While the company faces near-term headwinds from patent expirations on key drugs and lacks immediate replacements, analysts suggest long-term investors should view this as a turnaround opportunity. With a century-long track record and several drug trials scheduled for 2026, Pfizer is expected to navigate this difficult period and return to growth, potentially offering both income and capital appreciation.

06/21/2026, 9:15 PM • The Motley Fool

Want to Retire on $500,000? 3 Stocks to Buy and Never Sell

Retiring on $500,000 is possible with the right strategy. The article recommends three high-dividend income stocks that could help achieve this goal: Ares Capital (10.6% yield), Energy Transfer (7.2% yield), and Pfizer (6.8% yield). Combined with Social Security benefits, these stocks could generate sufficient income for retirement, though diversification beyond three stocks is essential.

06/21/2026, 4:24 AM • The Motley Fool

Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?

Eli Lilly is thriving in the GLP-1 weight-loss drug market with strong sales growth, but offers minimal dividend yield of 0.6%. Pfizer, struggling with patent expirations and GLP-1 setbacks, offers a much higher 6.6% dividend yield. While Pfizer faces near-term headwinds, income-focused investors willing to accept risk may find value in its substantial dividend, though the payout ratio exceeding 100% raises concerns.

06/20/2026, 5:15 PM • The Motley Fool

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

Pfizer stock fell 2.74% following the announcement that CFO Dave Denton will depart in August, raising investor concerns about leadership continuity and the company's ability to meet 2026 guidance. While recent drug approvals strengthen the pipeline, the CFO transition creates uncertainty around financial execution and earnings recovery.

06/18/2026, 7:09 PM • The Motley Fool

FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens

The FDA approved an expanded indication for Merck's Capvaxive pneumococcal vaccine, extending its use to children and adolescents ages 2-17 with chronic conditions. The approval was based on Phase 3 STRIDE-13 trial data and makes Capvaxive the only pneumococcal conjugate vaccine specifically studied and indicated for this patient group in the U.S. The vaccine covers serotypes associated with approximately 79% of invasive pneumococcal disease cases among at-risk children.

06/18/2026, 11:29 AM • Benzinga

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

Bio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors

Bio Usawa, a biotechnology company focused on expanding access to biologic medicines in Africa, announced the appointment of Dr. Aida Habtezion, former Chief Medical Officer at Pfizer, to its Board of Directors. The appointment strengthens the company's governance as it advances its mission to build sustainable biomanufacturing capabilities on the continent.

06/15/2026, 4:00 AM • GlobeNewswire

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

Bristol Myers Squibb offers an attractive 4.5% dividend yield, well above market averages. While the company faces patent expirations on key drugs like Revlimid and Eliquis, its strong financial position, reasonable 72% payout ratio, investment-grade credit rating, and decades-long dividend history suggest the dividend is likely safe for most investors.

06/13/2026, 6:15 PM • The Motley Fool

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About

Pfizer's berobenatide, a GLP-1 receptor agonist anti-obesity drug, demonstrated comparable weight-loss results (15.9% at 32 weeks) to competitors but with a key advantage: monthly injections instead of weekly ones. With 10 trials in or entering phase 3 and 20+ anti-obesity treatments in development, Pfizer is positioning itself as a serious competitor to market leaders Eli Lilly and Novo Nordisk. However, significant revenue contributions won't materialize until 2029, and increased competition will likely erode pricing power for existing weight-loss drugs.

06/12/2026, 12:32 PM • The Motley Fool

Value Investors Question SpaceX's Record IPO: 'It's The Future That Kills You'

SpaceX completed the largest IPO in history, raising $75 billion at a $1.77 trillion valuation with shares priced at $135. However, value investors warn the company is overvalued at nearly 100 times sales, with its AI and technology operations still unprofitable. Critics argue the valuation assumes flawless execution and question whether future earnings can justify the premium paid today.

06/12/2026, 10:57 AM • Benzinga

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

Bristol Myers Squibb has maintained an 18-year dividend growth streak despite facing patent cliffs on flagship drugs like Eliquis. The company's $3.5 billion in planned cost savings by 2027 and a sustainable 40% payout ratio support continued dividend growth. With $10.5 billion in cash reserves, BMY appears well-positioned to maintain and grow its 4.5% dividend yield.

06/11/2026, 2:02 PM • The Motley Fool

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, representing a 40% premium. The deal reflects Big Pharma's aggressive capital deployment to address an impending patent cliff, as GSK faces revenue loss from dolutegravir's expiring exclusivity. Nuvalent brings two late-stage kinase inhibitors targeting non-small cell lung cancer with FDA Breakthrough Therapy designations, triggering a short squeeze and signaling potential industry consolidation in oncology.

06/11/2026, 1:18 PM • Investing

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

06/10/2026, 1:00 PM • GlobeNewswire

Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study

Pfizer reported Phase 2b study results for berobenatide, its investigational GLP-1 receptor agonist, showing 15.9% non-placebo-adjusted weight loss with no plateau at 32 weeks. The company plans to advance 10 Phase 3 studies in 2026 for chronic weight management and obesity-related conditions. Additionally, the FDA approved an expanded indication for Pfizer's HYMPAVZI for hemophilia patients. PFE shares declined 1.3% to $25.70 at publication.

06/08/2026, 2:06 PM • Benzinga

3 Dividend Stocks to Buy Hand Over Fist in June

The article recommends three dividend-paying investments for June: Pfizer (6.7% yield) despite patent expiration challenges but with a strong drug pipeline, United Parcel Service (7.7% yield) which is shifting away from low-margin Amazon deliveries toward higher-margin customers, and the Schwab U.S. Dividend Equity ETF (3.25% yield) offering diversified dividend exposure across ~100 companies.

06/07/2026, 1:30 AM • The Motley Fool